Cargando…

Analysis of gene expression signatures identifies prognostic and functionally distinct ovarian clear cell carcinoma subtypes

BACKGROUND: Ovarian clear cell carcinoma (OCCC) is a histological subtype of epithelial ovarian cancer (EOC) with distinct pathological, biological, and molecular features. OCCCs are more resistant to conventional treatment regimen of EOC and have the worst stage-adjusted prognosis amongst EOC subty...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tan, Tuan Zea, Ye, Jieru, Yee, Chung Vin, Lim, Diana, Ngoi, Natalie Yan Li, Tan, David Shao Peng, Huang, Ruby Yun-Ju
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Research paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6921362/ https://www.ncbi.nlm.nih.gov/pubmed/31761620 http://dx.doi.org/10.1016/j.ebiom.2019.11.017

Ejemplares similares

A multi‐ethnic analysis of immune‐related gene expression signatures in patients with ovarian clear cell carcinoma
por: Heong, Valerie, et al.
Publicado: (2021)

CSIOVDB: a microarray gene expression database of epithelial ovarian cancer subtype
por: Tan, Tuan Zea, et al.
Publicado: (2015)

The role of GRHL2 and epigenetic remodeling in epithelial–mesenchymal plasticity in ovarian cancer cells
por: Chung, Vin Yee, et al.
Publicado: (2019)

SNAI1-Driven Sequential EMT Changes Attributed by Selective Chromatin Enrichment of RAD21 and GRHL2
por: Sundararajan, Vignesh, et al.
Publicado: (2020)

Correction: Sundararajan, V., et al. SNAI1-Driven Sequential EMT Changes Attributed by Selective Chromatin Enrichment of RAD21 and GRHL2. Cancers 2020, 12, 1140
por: Sundararajan, Vignesh, et al.
Publicado: (2020)

Functional relevance of a six mesenchymal gene signature in epithelial-mesenchymal transition (EMT) reversal by the triple angiokinase inhibitor, nintedanib (BIBF1120)
por: Huang, Ruby Yun-Ju, et al.
Publicado: (2015)

GRHL2-miR-200-ZEB1 maintains the epithelial status of ovarian cancer through transcriptional regulation and histone modification
por: Chung, Vin Yee, et al.
Publicado: (2016)

Identification of serum cytokine clusters associated with outcomes in ovarian clear cell carcinoma
por: Yabuno, Akira, et al.
Publicado: (2020)

Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer
por: Tan, Tuan Zea, et al.
Publicado: (2013)

The FZD7‐TWIST1 axis is responsible for anoikis resistance and tumorigenesis in ovarian carcinoma
por: Tan, Ming, et al.
Publicado: (2019)

SNAI1 recruits HDAC1 to suppress SNAI2 transcription during epithelial to mesenchymal transition
por: Sundararajan, Vignesh, et al.
Publicado: (2019)

Nuclear pCHK1 as a potential biomarker of increased sensitivity to ATR inhibition
por: Sundararajan, Vignesh, et al.
Publicado: (2022)

Comprehensive assessment of the expression of the SWI/SNF complex defines two distinct prognostic subtypes of ovarian clear cell carcinoma
por: Abou-Taleb, Hisham, et al.
Publicado: (2016)

An integrative multi-omics analysis based on disulfidptosis-related prognostic signature and distinct subtypes of clear cell renal cell carcinoma
por: Zhang, Dong, et al.
Publicado: (2023)

Genomic Sub-Classification of Ovarian Clear Cell Carcinoma Revealed by Distinct Mutational Signatures
por: Oliveira, Douglas V. N. P., et al.
Publicado: (2021)

Angiogenesis-Related Molecular Subtypes and a Novel Prognostic Signature in Clear Cell Renal Cell Carcinoma Patients
por: Li, Hao, et al.
Publicado: (2021)

Cysteine Deprivation Targets Ovarian Clear Cell Carcinoma Via Oxidative Stress and Iron−Sulfur Cluster Biogenesis Deficit
por: Novera, Wisna, et al.
Publicado: (2020)

3D genome organization in the epithelial-mesenchymal transition spectrum
por: Pang, Qing You, et al.
Publicado: (2022)

Histological Subtypes Drive Distinct Prognostic Immune Signatures in Classical Hodgkin Lymphoma
por: Lamaison, Claire, et al.
Publicado: (2022)

A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician’s choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA)
por: Ngoi, Natalie YL, et al.
Publicado: (2020)

Integrative genomic and transcriptomic analysis reveals immune subtypes and prognostic markers in ovarian clear cell carcinoma
por: Ye, Shuang, et al.
Publicado: (2022)

Proteomic characterization of epithelial ovarian cancer delineates molecular signatures and therapeutic targets in distinct histological subtypes
por: Gong, Ting-Ting, et al.
Publicado: (2023)

PD-L1 Expressing Recurrent Clear Cell Carcinoma of the Vulva with Durable Partial Response to Pembrolizumab: A Case Report
por: Sachdeva, Manavi, et al.
Publicado: (2021)

Identification of an apoptosis-related prognostic gene signature and molecular subtypes of clear cell renal cell carcinoma (ccRCC)
por: Zhong, Weimin, et al.
Publicado: (2021)

Identification and validation of the molecular subtype and prognostic signature for clear cell renal cell carcinoma based on neutrophil extracellular traps
por: Quan, Jing, et al.
Publicado: (2022)

Update on immune checkpoint inhibitors in gynecological cancers
por: Heong, Valerie, et al.
Publicado: (2017)

Identification of an immune subtype-related prognostic signature of clear cell renal cell carcinoma based on single-cell sequencing analysis
por: Fan, Zongyao, et al.
Publicado: (2023)

The effect of inhibition of receptor tyrosine kinase AXL on DNA damage response in ovarian cancer
por: Yeo, Xun Hui, et al.
Publicado: (2023)

The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?
por: Ngoi, N.Y.L., et al.
Publicado: (2021)

Lipidomic Analysis of Archival Pathology Specimens Identifies Altered Lipid Signatures in Ovarian Clear Cell Carcinoma
por: Mir, Sartaj Ahmad, et al.
Publicado: (2021)

Author Correction: The effect of inhibition of receptor tyrosine kinase AXL on DNA damage response in ovarian cancer
por: Yeo, Xun Hui, et al.
Publicado: (2023)

Integrative network analysis identifies an immune-based prognostic signature as the determinant for the mesenchymal subtype in epithelial ovarian cancer
por: Sheng, Mingyan, et al.
Publicado: (2020)

Analysis of Autophagy-Related Signatures Identified Two Distinct Subtypes for Evaluating the Tumor Immune Microenvironment and Predicting Prognosis in Ovarian Cancer
por: Chen, Xingyu, et al.
Publicado: (2021)

Distinct neural signatures of cognitive subtypes of dyslexia with and without phonological deficits()
por: van Ermingen-Marbach, Muna, et al.
Publicado: (2013)

Distinct molecular subtypes of systemic sclerosis and gene signature with diagnostic capability
por: Wang, Qi, et al.
Publicado: (2023)

The 4th European Society for Medical Oncology Asia Congress: bridging ultimate cancer care with real-world practice for the Asian practitioner in gynecological cancers
por: Ngoi, Natalie YL, et al.
Publicado: (2019)

Identification of three molecular subtypes based on immune infiltration in ovarian cancer and its prognostic value
por: Liu, Juan, et al.
Publicado: (2020)

Integrative analysis of transcriptomic landscape and urinary signature reveals prognostic biomarkers for clear cell renal cell carcinoma
por: Zhang, Wei, et al.
Publicado: (2023)

Prognostic assessment of sarcomatous histologic subtypes of ovarian carcinosarcoma
por: Kim, Hyun Jin, et al.
Publicado: (2017)

The Prognostic 97 Chemoresponse Gene Signature in Ovarian Cancer
por: Matondo, Abel, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_83jtn5ckpj69q7f975plvud79r